Xtant Medical Holdings and Dilon Technologies announced a strategic distribution agreement for HEMOBLAST Bellows in the United States. The company aims to expand access to advanced surgical hemostasis solutions across hospitals. Moreover, the deal strengthens Xtant Medical’s commercial footprint in a rapidly growing surgical device market.
Xtant Medical agreed to obtain exclusive U.S. distribution rights for Dilon’s HEMOBLAST Bellows product. The collaboration focuses on improving surgical bleeding control during complex procedures. Additionally, the companies highlighted a projected $2.0 billion global addressable market for hemostatic products, signaling strong long-term growth potential.
HEMOBLAST serves as a pre-loaded hemostatic powder designed for use when conventional methods fail. It supports surgeons in controlling minimal, mild, and moderate bleeding across various surgical settings. Furthermore, the product uses a combination of collagen, thrombin, and chondroitin sulfate to enhance clot formation efficiency. This composition positions HEMOBLAST as a differentiated solution in surgical care.
Xtant Medical will integrate Dilon’s approximately 20-member U.S. sales team into its organization. Consequently, the company expects stronger market penetration and improved customer engagement nationwide. The integration also allows Xtant to expand its distribution capabilities without building an entirely new sales infrastructure. As a result, operational efficiency may improve in the short term.
The agreement also reflects Xtant Medical’s broader strategy to diversify its product portfolio. In addition, the company continues to focus on orthobiologics and spinal implant solutions. Therefore, HEMOBLAST adds a complementary surgical tool that enhances its existing offerings. This diversification may help the company compete more effectively in the medical technology sector.
HEMOBLAST will be distributed in the United States under exclusive rights granted to Xtant Medical. Meanwhile, Dilon Technologies will continue manufacturing the product and supplying it under contractual terms. This structure ensures consistent product availability while allowing Xtant to focus on commercialization. Consequently, both companies benefit from a streamlined operational model.
Xtant Medical also paid a $5.0 million exclusivity fee to secure the agreement. However, the companies structured the payment with certain conditional protections. This investment signals confidence in HEMOBLAST’s commercial potential and long-term revenue contribution. Therefore, stakeholders are closely monitoring the financial impact of this strategic move.
The collaboration arrives as hospitals demand more effective and easy-to-use hemostatic solutions. In particular, surgical teams increasingly prefer products that reduce preparation time and improve efficiency. HEMOBLAST’s pre-loaded applicator supports this trend by eliminating complex preparation steps. As a result, it may gain rapid adoption in operating rooms.
Xtant’s leadership emphasized that the agreement expands its addressable market significantly. Moreover, the company believes the integration of Dilon's sales force will accelerate commercialization efforts. Consequently, Xtant expects stronger engagement with surgeons and healthcare providers across the United States. This alignment supports its long-term growth strategy.
Industry analysts view the hemostatic market as highly competitive yet expanding. Therefore, companies with differentiated products and strong distribution networks may gain an advantage. HEMOBLAST’s unique formulation could help Xtant strengthen its position in this space. Meanwhile, execution will remain critical to realizing projected benefits.
Overall, the agreement marks a key milestone for both Xtant Medical and Dilon Technologies. Additionally, it reflects increasing collaboration within the medical device industry to expand product reach. With HEMOBLAST at the center, Xtant aims to scale its presence in surgical care markets. Ultimately, the partnership could reshape its growth trajectory in the coming years.
